TherimuneX Pharmaceuticals Inc scientists are investigating a new signaling molecule that is induced in response to cell injury that initiates an innate-immune response mediated by the inflammasome complex and specific gene transcription regulators. The firm has discovered an inhibitor that down-regulates the inflammasome signaling cascade. This proprietary knowledge of the inflammasome signaling scaffold is being used as a platform for elucidating new drugable targets and drug-like molecules with applications to a wide a variety of disease pathologies, supporting development of a new family of endogenous lipopeptides and their immune regulating properties. The TherimuneX scientific discovery has led to the development of a new therapeutic peptide for treating and preventing infectious diseases. Areas of focus include Scleroderma, Oncology, Infectious Disease, Alzheimer's
